Source: Virtual Congress 2021 – Wheezing illnesses along the life span



Rating:

Share or cite this content

Citations should be made in the following way:
F. Di Marco (Trezzano Sul Naviglio (MI), Italy). Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes. Virtual Congress 2021 – Wheezing illnesses along the life span

Member's Comments

No comment yet.

Related content which might interest you: SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 Implementation of NO measurement in the daily practice leads to more confident astma diagnosis and has important effects on anti-inflammatory treatment Source: Eur Respir J 2007; 30: Suppl. 51, 553s Year: 2007 Feedback on inhaler use does not significantly improve inhaled corticosteroid adherence or clinical outcomes Source: Virtual Congress 2020 – Digital technologies in airway diseases Year: 2020 Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001 Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment Source: Eur Respir J 2015; 45: 260-262 Year: 2015 Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002 Optimal adherence with inhaled corticosteroids is related to better health status Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Asthma-related resource use and costs for patients prescribed inhaled corticosteroids compared to leukotriene modifiers in clinical practice Source: Annual Congress 2010 - Management of airway disease Year: 2010 How can we minimise the use of regular oral corticosteroids in asthma? Source: Eur Respir Rev, 29 (155) 190085; 10.1183/16000617.0085-2019 Year: 2020 Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Evaluation of prolonged bupropion treatment as an aid in smoking cessation Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002 Changes in the use of anti-asthmatic medication in an international cohort Source: Eur Respir J 2005; 26: 1047-1055 Year: 2005 Evidence of the effectiveness and safety of first-line smoking cessation pharmacotherapy Source: Eur Respir Monogr 2021; 90: 97-117 Year: 2021 An intervention to modify patients‘ beliefs about maintenance therapy and improve adherence to medication Source: Eur Respir J 2005; 26: Suppl. 49, 46s Year: 2005 How effective are oral steroids in asthma action plans? Source: International Congress 2017 – Asthma management Year: 2017 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007